Europe
December is bringing frost in the North and plenty of cold, hard cash for these life sciences companies.
Investors in the fund include a variety of existing and new limited partners, both groups made up of specialized institutional and corporate investors.
Swiss medtech company Abionic SA announced that they have developed the first COVID-19 severity test, the cSOFA (Covid Sequential Organ Failure Assessment) score, to help doctors quickly and accurately triage cases that come into emergency rooms.
The collaboration with Atara will focus on developing an off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
A dual treatment approach consisting of gemcitabine combined with AB Science’s masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
Governments across the globe have flexed their financial muscles to secure promises of as many doses of COVID-19 vaccines as possible when they become available.
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES